Stroke
Conditions
Brief summary
Clinical efficacy and safety of Metamizole 2 g i.v. versus placebo, as antithermic therapy in the acute phase of ischemic stroke.
Interventions
DRUGMetamizole
DRUGPlacebo
Sponsors
Boehringer Ingelheim
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age over 18 years * Hemispherical cerebral infarction with moderate (SSS = 30-44 points) or severe (SSS \< 30 points) deficit at the time of inclusion. However, only patients with a score between 15 and 44 points on the SSS scale will be included * Tympanic temperature between 37 and 38 degrees Celsius. The relationship between tympanic and body temperature is as follows: tympanic temperature = body temperature + 0.3 degrees Celsius * Onset of cerebral infarction symptoms within the last 24 hours. When the time of onset of symptoms is unknown (e.g. ictus occurred while sleeping) the last time when the patient was asymptomatic will be considered as time of onset * Normal cerebral CT scan or with signs of cerebral infarction * Patient's written or orally witnessed informed consent in accordance with local legislation, guidelines of Good Clinical Practice (GCP) and International Conference on Harmonization (ICH)-GCP
Exclusion criteria
* Patients with a history of granulocytopenia, thrombocytopenia or aplastic blood diseases of any etiology. Known hypersensitivity to salicylates, pyrazolones and other nonsteroidal antiinflammatory drugs (NSAIDs). NSAID-induced bronchial asthma * Patients with a history indicating a life expectancy less than 30 days or patients whom the investigator thinks that it will not be possible to follow for entire 30 days * Non-cooperative * Patients with neurological sequelae of a previous stroke * Cerebral hemorrhage * Pregnancy, lactation * Participation in another clinical trial * Intake of acetylsalicylic acid (ASA) \> 300 mg per day, paracetamol or NSAIDs during the 24 hours prior to administration of the study medication * Seizures at the start of the stroke
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Assessment of the functional outcome according to the Scandinavian Stroke Scale (SSS) | after 30 days |
Secondary
| Measure | Time frame |
|---|---|
| Number of patients with score of SSS < 30 points | after 30 days |
| Clinical impression assessed on the Modified Rankin Scale | after 30 days |
| Effect on the activities of daily living assessed on Barthel Index | after 30 days |
| Number of patients requiring rescue therapy | up to 30 days |
| Assessment of functional outcome according to SSS | Baseline, after 3 and 7 days |
| Assessment of tympanic temperature | up to 3 days after start of treatment |
| Percentage of mortality | after 30 days |
| Number of patients with adverse events | up to 30 days |
| Duration of hospital stay | up to 30 days |
Outcome results
None listed